# OnCo record tki-term (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/tki-term/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "tki-term" ;
  schema:name "Tyrosine kinase inhibitor (TKI)"@en ;
  schema:alternateName "TKI"@en, "TKIs"@en, "tyrosine kinase inhibitors"@en, "kinase inhibitor"@en, "multikinase inhibitor"@en, "multi-kinase inhibitor"@en, "multi-targeted TKI"@en, "EGFR-TKI"@en, "ALK TKI"@en, "BTK inhibitor"@en, "BTK inhibitors"@en, "BTK inhibition"@en, "targeted pill"@en, "-nib"@en, "TKI-pretreated"@en, "TKI-naive"@en, "first-generation"@en, "second-generation"@en, "third-generation"@en, "next-generation TKI"@en, "kinase inhibitors"@en, "multikinase inhibitors"@en, "next-generation TKIs"@en, "targeted pills"@en ;
  schema:description "Pills that block the on-switch enzyme (a kinase) that a particular cancer depends on: imatinib for CML, osimertinib for EGFR lung cancer, ibrutinib for CLL. Usually taken daily at home and continued as long as they work."@en ;
  schema:url <https://onco.cc/terms/tki-term/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor> ;
  schema:citation <https://en.wikipedia.org/wiki/Tyrosine_kinase_inhibitor> ;
  onco:related <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/rash-skin-toxicity/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/cabozantinib/> .